# TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Source: https://onco.cc/trials/nct07082803/  
OnCo record `nct07082803` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of TLN-121 run by Treeline Biosciences, Inc., now recruiting.

## Summary

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas is a phase 1 interventional study registered as NCT07082803 by Treeline Biosciences, Inc., with 180 participants planned, started 2025-06-23. Conditions recorded: Lymphoma and Lymphoma, Non Hodgkin. Interventions recorded: TLN-121, zeprumetostat (TLN-254) and TLN-121.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07082803
- Phase: 1
- Setting: An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Sponsor: Treeline Biosciences, Inc.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07082803: https://clinicaltrials.gov/study/NCT07082803

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [TLN-121](https://onco.cc/drugs/tln-121/), [Zeprumetostat](https://onco.cc/drugs/zeprumetostat/)
- companies: [Treeline Biosciences](https://onco.cc/companies/treeline-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07082803.json